

Meeting of the Council

May 4, 2007

Present:

President and District 1 councillor Randy Konrad; District 2 Councillor Bev Harris; District 3 councillor Barry Wilson; District 4 councillor Erica Gregory; District 5 Councillor Rita Thomson; District 7 councillor Carol Gee; Government Appointees Marina Ma and Michael MacDougall; Faculty of Pharmaceutical Sciences Dean Robert Sindelar

Absent (with notice):

Government Appointees Margaret Cleaveley & Winnie Wong; District 6 councillor James Kim

Staff (at various times):

Registrar Marshall Moleschi; Deputy Registrar Suzanne Solven; Executive Assistant April Lightbown; General Manager Susan Lo.

Guests (at various times):

RPh Director UBC CPPD Janice Moshenko; Deputy CEO & Director, BCPhA Ken McCartney,

1. Welcome and Call to Order

- President Konrad called the meeting to order at 9:05 a.m.
- He stated the college mission statement:

To ensure British Columbia pharmacists provide safe and effective pharmacy care to help people achieve better health.

2. Agenda and Timetable

- It was moved, seconded and carried that the following items be added to the agenda:
 - i. Review of committees
 - ii. Benchmarking
 - iii. Council assessment
- The agenda and timetable were approved with additions.

3. Previous Meeting Minutes

- The minutes of the February 9, 2007 council meeting were approved by consensus.

4. Outcome Development Issues

4.01 Internal (college/council)

- The registrar circulated a report of activities related to strategic goals as of May 2007.
- The deputy registrar provided an update with respect to the strategic planning process that will take place at the June council meeting. The purpose of the session is to review the current strategic plan that is now one year old. The session will include a review and/or development of: vision, mission, strategic goals, and performance measures.

4.02 External (pharmacists/public)

- No topics

5. New Policy Development

- No topics

6. Monitoring Activities

6.01 Registrar's Executive Report

- The registrar provided monitoring reports and updates on the following topics:

❖ *DO-1 Stakeholder Relations*

Activities and events relating to stakeholder relations were provided for the information of the councillors.

❖ *DO-2 Practice Standards: General*

Activities and events relating to practice standards: general were provided for the information of the councillors.

❖ ***DO-3b Practice Standards: Professional Development and Assessment Program***

Activities and events relating to the professional development and assessment program were provided and discussed. Below is a summary:

- The registrar presented to the board of examiners on April 17, 2007.
- The board passed a motion to appoint a task force to explore options for the development of a CE based tool for the PDAP.
- The board recommended that the task force include appointees from the following: council member (1), BCPhA representative (1), UBC faculty (1), UBC continuing pharmacy professional development (1), hospital pharmacists (2), community pharmacists (2) and board of examiners (3).
- The board anticipates that the group would need to meet 3 times (1/2 day, 1 day, ½ day). College staff are working towards the first meeting to take place in June.
- A copy of the Manitoba competency assessment program was distributed and discussed.

ACTION: The registrar will circulate to council the opportunity to put forward their name to sit on the task force.

ACTION: The registrar will report back on progress at the June council meeting.

❖ ***DO-5 Professionalism***

No specific activities were targeted to this outcome during the reporting period.

❖ ***DO-8 Pharmacy Technicians***

The hospital pharmacy committee is continuing to review issues and develop proposals relating to the expanded scope of practice for hospital pharmacy technicians.

❖ ***DO-9 Pharmacist Empowerment and Autonomy***

Various activities relating to the promotion of pharmacist empowerment and autonomy were reported.

- There are ongoing discussions about medication management (often termed pharmacists prescribing) with BCPhA, the College of Physicians and Surgeons, MLA's and the Ministry of Health.
- The registrar and deputy registrar have consulted college and government lawyers, and the person who lead the development of the PPODS act to clarify pharmacists' authority to make decisions concerning medication management.
- The registrar presented the Alberta College of Pharmacists' new practice standards which includes pharmacists prescribing. He discussed how two of the standards can be accommodated in the current PPODS act. In British Columbia these activities are currently referred to as medication management.
- The next step will be for the college to develop a framework for medication management. The registrar proposed this framework be further discussed at the June council meeting.

❖ ***DO-11 Involving Pharmacists in Key Initiatives***

Various activities relating to the promotion of pharmacist empowerment and autonomy were reported.

❖ ***EC-3 Financial Health***

The college general manager presented the 2006–07 interim financial statements.

- The statements are still to be consolidated with results of the building joint venture.
- The statements will be audited in May 2007 and will be available for approval in June/July 2007.
- Budget variances were also discussed. The general manager will be meeting with the auditors on May 7, 2007.
- The registrar provided a cash flow analysis for fiscal 2007/08.

❖ ***EC-10 Communication Reporting: Registrar to Council***

The registrar reported full compliance with this policy's requirements.

❖ ***EC-13 Charitable Donations***

The registrar reported full compliance with this policy's requirements.

❖ ***CSR-2 Authority Delegated to the Registrar***

The registrar reported full compliance with this policy's requirements.

❖ ***CG-3 Committees***

a) Audit committee

The registrar informed council that the audit committee requires two new appointments.

It was moved, seconded and carried:

Council appoints past president Rita Thomson and District 2 Councillor Bev Harris to the audit committee.

b) Inquiry committee

It was moved, seconded and carried:

Council appoints Jing-Yi Ng to the inquiry committee.

c) Ethics committee

An ethics committee meeting was held on Wednesday May 3, 2007. Pharmacist Christine Alarcon presented her paper on *Code of Ethics Value VIII: The need to accommodate conscience and religion in the pharmacy profession.*

❖ ***CG-5 Role of the President***

The requirements of the council policy on the role of the president have been met.

❖ ***CG-7 Relationship with the Public and Other Key Stakeholders***

Activities and events relating to relations with the public and other key stakeholders were provided to demonstrate compliance with the policy.

❖ ***PPP-1 Tobacco-free Pharmacies***

No new activities or events.

❖ ***PPP-52 Medication Packaging for Facilities***

No new activities or events.

6.02 Council Monitoring Reports

❖ ***CSR-1 Registrar's Job Description***

The requirements of the council policy on the registrar's job description have been met.

❖ ***CG-2 Governance Style***

The requirements of the council policy on governance style have been met.

7. Nonpolicy decisions

- no topics

8. Operational constraints development

- no topics

9. Consent items

9.01 Drug scheduling recommendations

It was moved, seconded and carried:

Council approves that the B.C. Drug Schedule be amended as follows:

Deletion of:

- 1 Famotidine and its salts (except in preparations for oral use containing 10 mg or less of famotidine per dosage unit)
- 3 Fexofenadine hydrochloride

- 3 Hydrocortisone (as a single ingredient in topical preparations in concentration of 0.5% or less)
- 1 Hydrocortisone^v (except as a single ingredient in topical preparations in concentrations of 0.5% or less)
- 3 Hydrocortisone acetate (as a single ingredient in topical preparations in concentrations of 0.5% or less)
- 1 Hydrocortisone acetate^v (except as a single ingredient in topical preparations in concentrations of 0.5% or less)
- 2 Loperamide and its salts (oral liquid dosage forms for children)
- 2 Loperamide and its salts (in other than solid dosage forms)
- 1 Ranitidine and its salts (except oral tablets in strengths of 75 mg or less)

Addition of:

- 1 Adalimumab
- 1 Alefacept
- 1 Alemtuzumab
- 1 Atomoxetine and its salts
- 1 Azelaic acid
- 1 Bevacizumab
- 1 Cetuximab
- 1 Choriogonadotropin alfa
- 1 Cinacalcet and its salts
- 1 Darifenacin and its salts
- 1 Efalizumab
- 1 Eletriptan and its salts
- 1 Emtricitabine
- 1 Escitalopram and its salts
- 1 Famotidine and its salts (except when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn)
- 2 Famotidine and its salts (when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 600 mg of famotidine)
- 3 Fexofenadine hydrochloride (in products marketed for pediatric use—under 12 years of age)
- 1 Frovatriptan and its salts
- 1 Hydrocortisone^v (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)
- 3 Hydrocortisone (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

- 1 Hydrocortisone acetate^v (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)
- 3 Hydrocortisone acetate (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)
- 2 Loperamide and its salts (in products marketed for pediatric use—under 12 years of age)
- 1 Nitric oxide
- 1 Omalizumab
- 1 Palifermin
- 1 Paricalcitol
- 1 Pegaptanib and its salts
- 1 Pegvisomant
- 1 Ranitidine and its salts (except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn)
- 2 Ranitidine and its salts (when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4500 mg of ranitidine)
- 1 Tipranavir and its salts
- 1 Voriconazole

10. Council Development

10.01 Governance Workshop

- A morning session, facilitated by Sage Consulting, was held with respect to policy governance.

10.02 Provincial Legislation Process

- Daryl Beckett, Director Professional Regulation at the Ministry of Health discussed with council the transition of the *Pharmacists, Pharmacy Operations and Drug Scheduling Act* to the Health Professions Act and the Pharmacy Operations and Drug Scheduling Act.
- Mr. Beckett indicated that the transition is expected to take place in spring 2008.

11. Review of Committees

- Council expressed an interest in reviewing the current committees of the College of Pharmacists of BC.

ACTION: For the June council meeting the registrar will provide a list of all committees. For each committee the following items will also be provided: terms of reference, reporting and accountability structure, process for appointment of members and the chair, terms of reference and minutes for the past year.

12. Benchmarking

- A councillor requested that council give some thought to developing standards that could be regularly reported for benchmarking activities of the college.

ACTION: Councillors and college staff review meaningful metrics that could be provided at every council meeting. Item to be reviewed at the June council meeting.

13. Council Assessment

- Council discussed the need for an evaluation process to review both the performance of council as a whole and of individual councillors.
- It was suggested that a third party be brought in to facilitate this process.

ACTION: Councillors were encouraged to forward their ideas/thoughts to the registrar.

ACTION: The registrar will bring proposed recommendations and options to the June council meeting.

14. Meeting assessment and adjournment